Suppr超能文献

从口服避孕药转换为经皮或经阴道避孕药对血栓形成标志物的影响。

Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis.

作者信息

Jensen Jeffrey T, Burke Anne E, Barnhart Kurt T, Tillotson Carrie, Messerle-Forbes Marci, Peters Dawn

机构信息

Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR 97239, USA.

出版信息

Contraception. 2008 Dec;78(6):451-8. doi: 10.1016/j.contraception.2008.07.004. Epub 2008 Aug 28.

Abstract

BACKGROUND

The study was conducted to determine the impact of switching from oral to transdermal patch or vaginal ring contraception on biomarkers of thrombosis.

STUDY DESIGN

Current healthy oral contraceptive (OC) users were randomized to switch to either a contraceptive ring (CR) or patch (CP) and underwent phlebotomy to measure surrogate biomarkers of thrombosis [sex hormone-binding globulin (SHBG), free protein S and activated protein C resistance (APC-r)] before switching, and during the fourth cycle of use of the new method.

RESULTS

Of 142 reproductive age women enrolled, 120 sample pairs were available for analysis. SHBG increased significantly from baseline in CP users [mean change (95% CI), +29.9 nM (9.6-50)] but not in CR users [-1.6 (-16.6 to 13.5)]. Protein S decreased significantly from baseline in CP users [mean change -7.1% (-12.1 to -2.1)], but increased significantly in CR users [+5.3% (1.1-9.6)]. The APC-r ratio did not undergo a significant change from baseline in either group [CP +0.06 (-0.06 to 0.18), CR +0.02 (-0.10 to 0.14)]. Compared to CR users, subjects using the CP had significantly higher SHBG [187.5 (167.0-208), 146 (132.6-159.4), p=.012], significantly lower protein S [81.8 (76.8-86.8), 93.6 (89.1-98.1), p=.001] and similar APC-r ratios [2.99 (2.85-3.14), 3.09 (2.96, 3.22), p=.3] at the Cycle 4 visit.

CONCLUSION

OC users who switch to the ring exhibit beneficial changes in biomarkers of thrombosis, while those switching to the patch display a shift favoring clot formation.

摘要

背景

本研究旨在确定从口服避孕药转换为透皮贴剂或阴道环避孕对血栓形成生物标志物的影响。

研究设计

当前健康的口服避孕药(OC)使用者被随机分配转换为避孕环(CR)或贴片(CP),并在转换前以及新方法使用的第四个周期期间进行静脉穿刺以测量血栓形成的替代生物标志物[性激素结合球蛋白(SHBG)、游离蛋白S和活化蛋白C抵抗(APC-r)]。

结果

在纳入的142名育龄妇女中,有120对样本可用于分析。CP使用者的SHBG较基线显著升高[平均变化(95%CI),+29.9 nM(9.6 - 50)],而CR使用者则未升高[-1.6(-16.6至13.5)]。CP使用者的蛋白S较基线显著降低[平均变化-7.1%(-12.1至-2.1)],而CR使用者则显著升高[+5.3%(1.1 - 9.6)]。两组的APC-r比值与基线相比均未发生显著变化[CP +0.06(-0.06至0.18),CR +0.02(-0.10至0.14)]。在第4周期访视时,与CR使用者相比,使用CP的受试者SHBG显著更高[187.5(167.0 - 208),146(132.6 - 159.4),p = 0.012],蛋白S显著更低[81.8(76.8 - 86.8),93.6(89.1 - 98.1),p = 0.001],且APC-r比值相似[2.99(2.85 - 3.14),3.09(2.96,3.22),p = 0.3]。

结论

转换为阴道环的OC使用者在血栓形成生物标志物方面表现出有益变化,而转换为贴片的使用者则表现出有利于血栓形成的变化。

相似文献

1
Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis.
Contraception. 2008 Dec;78(6):451-8. doi: 10.1016/j.contraception.2008.07.004. Epub 2008 Aug 28.
2
Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives.
J Thromb Haemost. 2012 Jun;10(6):992-7. doi: 10.1111/j.1538-7836.2012.04720.x.
3
Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study.
Thromb Res. 2009;123(3):429-35. doi: 10.1016/j.thromres.2008.04.022. Epub 2008 Sep 30.
7
Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives.
Thromb Res. 2014 Apr;133(4):640-4. doi: 10.1016/j.thromres.2013.12.041. Epub 2014 Jan 7.
8
Sex hormone-binding globulin and thrombin generation in women using hormonal contraception.
Biomarkers. 2017 Feb;22(1):81-85. doi: 10.1080/1354750X.2016.1204010. Epub 2016 Jul 6.
9
Effects of oral contraceptives on hemostasis and thrombosis.
Am J Obstet Gynecol. 1999 Jun;180(6 Pt 2):S375-82. doi: 10.1016/s0002-9378(99)70699-x.
10
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
Lancet. 1999 Dec 11;354(9195):2036-40. doi: 10.1016/s0140-6736(99)06092-4.

引用本文的文献

1
Pharmacists and Contraception in the Inpatient Setting.
Pharmacy (Basel). 2020 May 9;8(2):82. doi: 10.3390/pharmacy8020082.
2
Nonoral combined hormonal contraceptives and thromboembolism: a systematic review.
Contraception. 2017 Feb;95(2):130-139. doi: 10.1016/j.contraception.2016.10.005. Epub 2016 Oct 19.
3
Estrogen and thrombosis: controversies and common sense.
Rev Endocr Metab Disord. 2011 Jun;12(2):77-84. doi: 10.1007/s11154-011-9178-0.
4
Hormonal contraception and thrombotic risk: a multidisciplinary approach.
Pediatrics. 2011 Feb;127(2):347-57. doi: 10.1542/peds.2010-2221. Epub 2011 Jan 3.

本文引用的文献

1
Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial.
Obstet Gynecol. 2008 Feb;111(2 Pt 1):278-84. doi: 10.1097/AOG.0b013e3181626d1b.
2
Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial.
Obstet Gynecol. 2008 Feb;111(2 Pt 1):267-77. doi: 10.1097/01.AOG.0000298338.58511.d1.
3
Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables.
Contraception. 2008 Feb;77(2):77-83. doi: 10.1016/j.contraception.2007.10.004. Epub 2008 Jan 11.
5
Contraception for women with chronic medical conditions.
Obstet Gynecol Clin North Am. 2007 Mar;34(1):113-26, ix. doi: 10.1016/j.ogc.2007.02.001.
6
Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
Obstet Gynecol. 2007 Feb;109(2 Pt 1):339-46. doi: 10.1097/01.AOG.0000250968.82370.04.
7
Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins.
Contraception. 2006 Oct;74(4):293-6. doi: 10.1016/j.contraception.2006.04.005. Epub 2006 Jun 27.
8
Thrombophilia and women's health: An overview.
Obstet Gynecol Clin North Am. 2006 Sep;33(3):347-56. doi: 10.1016/j.ogc.2006.05.003.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验